000 | 01961 a2200589 4500 | ||
---|---|---|---|
005 | 20250516151716.0 | ||
264 | 0 | _c20140410 | |
008 | 201404s 0 0 eng d | ||
022 | _a1873-3492 | ||
024 | 7 |
_a10.1016/j.cca.2013.05.008 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aO'Brien, Travis J | |
245 | 0 | 0 |
_aFirst report of warfarin dose requirements in patients possessing the CYP2C9*12 allele. _h[electronic resource] |
260 |
_bClinica chimica acta; international journal of clinical chemistry _cSep 2013 |
||
300 |
_a73-5 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 | _aAlleles |
650 | 0 | 4 | _aAmino Acid Substitution |
650 | 0 | 4 |
_aAnticoagulants _xmetabolism |
650 | 0 | 4 |
_aApolipoproteins E _xgenetics |
650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xgenetics |
650 | 0 | 4 | _aBase Sequence |
650 | 0 | 4 | _aBiotransformation |
650 | 0 | 4 | _aCytochrome P-450 CYP2C9 |
650 | 0 | 4 | _aDrug Dosage Calculations |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aGenotype |
650 | 0 | 4 | _aGenotyping Techniques |
650 | 0 | 4 | _aHeterozygote |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aMolecular Sequence Data |
650 | 0 | 4 | _aMutation |
650 | 0 | 4 |
_aThromboembolism _xenzymology |
650 | 0 | 4 |
_aVitamin K Epoxide Reductases _xgenetics |
650 | 0 | 4 |
_aWarfarin _xmetabolism |
700 | 1 | _aKidd, Robert S | |
700 | 1 | _aRichard, Craig A H | |
700 | 1 | _aHa, Ngoc-Han | |
700 | 1 | _aWitcher, Preston | |
700 | 1 | _aTran, Linda V | |
700 | 1 | _aBarbour, April | |
700 | 1 | _aTuck, Matthew | |
700 | 1 | _aMcIntosh, Samantha D | |
700 | 1 | _aDouglas, Jacqueline N | |
700 | 1 | _aHarralson, Arthur F | |
773 | 0 |
_tClinica chimica acta; international journal of clinical chemistry _gvol. 424 _gp. 73-5 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.cca.2013.05.008 _zAvailable from publisher's website |
999 |
_c22765357 _d22765357 |